Influence of CYP2C19 and ABCB1 polymorphisms on plasma concentrations of lansoprazole enantiomers after enteral administration

An intraoral annihilation enteric-coated preparation of lansoprazole is often administered via intestinal fistula. The purpose of this study was to determine the plasma concentrations of lansoprazole enantiomers after enteral administration in subjects with cytochrome P4502C19 (CYP2C19) and ABCB1 C3435T genotypes. Fifty-one patients who underwent a curative oesophagectomy for oesophageal cancer were enrolled in this study. After a single enteral dose of racemic lansoprazole (30 mg), plasma concentrations of lansoprazole enantiomers were measured 4 h post-dose (C4h). There were significant differences in the C4h of (R)- and (S)-lansoprazole and the R/S-enantiomer ratio for three CYP2C19 genotype groups (*1/*1, *1/*2 ± *1/*3, and *2/*2 ± *2/*3 ± *3/*3 (poor metabolizers (PMs)), but not the ABCB1 C3435T genotypes. In a stepwise forward selection multiple regression analysis, the C4h of (R)- and (S)-lansoprazole were associated with CYP2C19 PMs (p = 0.0005 and < 0.0001 respectively) and age (p = 0.0040 and 0.0121 respectively), while the R/S-enantiomer ratio was associated with CYP2C19*1/*1 (p = 0.0191) and CYP2C19 PMs (p = 0.0426). Direct administration to the jejunum is unaffected by residence time in the stomach and the gastric emptying rate. With enteral administration, CYP2C19 phenotyping of patients using the lansoprazole R/S enantiomer index at C4h could be possible.

[1]  S. Motoyama,et al.  Correlation between R/S enantiomer ratio of lansoprazole and CYP2C19 activity after single oral and enteral administration. , 2009, Chirality.

[2]  S. Yamada,et al.  Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects , 2009, European Journal of Clinical Pharmacology.

[3]  S. Motoyama,et al.  Proton Pump Inhibitors Relieve and Prevent Symptoms Related to Gastric Acidity after Esophagectomy , 2008, World Journal of Surgery.

[4]  M. Hayakari,et al.  Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers , 2008, European Journal of Clinical Pharmacology.

[5]  M. Hayakari,et al.  Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration , 2007, European Journal of Clinical Pharmacology.

[6]  T. Habuchi,et al.  Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metaboliser Renal Transplant Recipients , 2007, Clinical drug investigation.

[7]  M Miura,et al.  Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. , 2006, International journal of clinical pharmacology and therapeutics.

[8]  M. Miura.  Enantioselective disposition of lansoprazole and rabeprazole in human plasma. , 2006, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[9]  M. Sasaki,et al.  The Effect of Aging on the Relationship between the Cytochrome P450 2C19 Genotype and Omeprazole Pharmacokinetics , 2005, Clinical pharmacokinetics.

[10]  N. Yasui-Furukori,et al.  Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. , 2005, British journal of clinical pharmacology.

[11]  Y. Nimura,et al.  Acid and Duodenogastroesophageal Reflux after Esophagectomy with Gastric Tube Reconstruction , 2005, The American Journal of Gastroenterology.

[12]  T. Habuchi,et al.  Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  A. Rubinstein.  Colonic drug delivery. , 2005, Drug discovery today. Technologies.

[14]  N. Yasui-Furukori,et al.  Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes , 2004, European Journal of Clinical Pharmacology.

[15]  M. Miura,et al.  Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  B. Kremer,et al.  Quality of Life Associated with Surgery for Esophageal Cancer: Differences between Collar and Intrathoracic Anastomoses , 2004, World Journal of Surgery.

[17]  J. Chun,et al.  Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[18]  S. Fukudo,et al.  High Incidence of Reflux Esophagitis Observed by Routine Endoscopic Examination after Gastric Pull-up Esophagectomy , 2003, World Journal of Surgery.

[19]  K. Ohashi,et al.  Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole , 2002, Clinical pharmacology and therapeutics.

[20]  Ji-Young Park,et al.  Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19 , 2002, Clinical pharmacology and therapeutics.

[21]  M. Fromm,et al.  Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[22]  C. Gutschow,et al.  Denervated Stomach as an Esophageal Substitute Recovers Intraluminal Acidity With Time , 2001, Annals of surgery.

[23]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[24]  S. Higuchi,et al.  Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. , 1999, British journal of clinical pharmacology.

[25]  C. Nakamura,et al.  Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects , 1997, European Journal of Clinical Pharmacology.

[26]  A. Mclarty,et al.  Esophageal resection for cancer of the esophagus: long-term function and quality of life. , 1997, The Annals of thoracic surgery.

[27]  A. D. Rodrigues,et al.  Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.

[28]  C. Bonfils,et al.  Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.

[29]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[30]  G. Granneman,et al.  Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. , 1993, British journal of clinical pharmacology.

[31]  T. Andersson,et al.  Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers , 1992, Clinical pharmacokinetics.

[32]  H. Satoh,et al.  Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. , 1990, Journal of Pharmacology and Experimental Therapeutics.

[33]  H. Wynne,et al.  The effect of age upon liver volume and apparent liver blood flow in healthy man , 1989, Hepatology.

[34]  H. Wynne,et al.  Age-Related Changes in Liver Size and Hepatic Blood Flow , 1988 .

[35]  G. Marchesini,et al.  Galactose elimination capacity and liver volume in aging man , 1988, Hepatology.

[36]  H. Wynne,et al.  Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. , 1988, Clinical pharmacokinetics.

[37]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.